Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 7.28
TPI's Cash to Debt is ranked higher than
75% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. TPI: 7.28 )
TPI' s 10-Year Cash to Debt Range
Min: 1.04   Max: No Debt
Current: 7.28

Equity to Asset 0.93
TPI's Equity to Asset is ranked higher than
98% of the 728 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. TPI: 0.93 )
TPI' s 10-Year Equity to Asset Range
Min: -0.94   Max: 0.93
Current: 0.93

-0.94
0.93
Interest Coverage 21.26
TPI's Interest Coverage is ranked higher than
60% of the 454 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.71 vs. TPI: 21.26 )
TPI' s 10-Year Interest Coverage Range
Min: 20.57   Max: 9999.99
Current: 21.26

20.57
9999.99
F-Score: 6
Z-Score: 3.30
M-Score: -2.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.80
TPI's Operating margin (%) is ranked higher than
82% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.25 vs. TPI: 13.80 )
TPI' s 10-Year Operating margin (%) Range
Min: -628.57   Max: 23.06
Current: 13.8

-628.57
23.06
Net-margin (%) 9.88
TPI's Net-margin (%) is ranked higher than
78% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. TPI: 9.88 )
TPI' s 10-Year Net-margin (%) Range
Min: -628.57   Max: 18.83
Current: 9.88

-628.57
18.83
ROE (%) 6.81
TPI's ROE (%) is ranked higher than
72% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. TPI: 6.81 )
TPI' s 10-Year ROE (%) Range
Min: -49.44   Max: 19.49
Current: 6.81

-49.44
19.49
ROA (%) 6.06
TPI's ROA (%) is ranked higher than
81% of the 777 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. TPI: 6.06 )
TPI' s 10-Year ROA (%) Range
Min: -46.94   Max: 17.44
Current: 6.06

-46.94
17.44
ROC (Joel Greenblatt) (%) 16.74
TPI's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.60 vs. TPI: 16.74 )
TPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -169.23   Max: 68.61
Current: 16.74

-169.23
68.61
Revenue Growth (%) 2.60
TPI's Revenue Growth (%) is ranked higher than
66% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TPI: 2.60 )
TPI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 457.2
Current: 2.6

0
457.2
EBITDA Growth (%) -7.60
TPI's EBITDA Growth (%) is ranked higher than
61% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. TPI: -7.60 )
TPI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 19.1
Current: -7.6

0
19.1
EPS Growth (%) -16.80
TPI's EPS Growth (%) is ranked higher than
60% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. TPI: -16.80 )
TPI' s 10-Year EPS Growth (%) Range
Min: -16.8   Max: 19.6
Current: -16.8

-16.8
19.6
» TPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TPI Guru Trades in Q3 2013

Jim Simons 410,500 sh (+3.06%)
» More
Q4 2013

TPI Guru Trades in Q4 2013

Jim Simons 488,700 sh (+19.05%)
» More
Q1 2014

TPI Guru Trades in Q1 2014

Jim Simons 620,100 sh (+26.89%)
» More
Q2 2014

TPI Guru Trades in Q2 2014

Jim Simons 680,100 sh (+9.68%)
» More
» Details

Insider Trades

Latest Guru Trades with TPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 2.90
TPI's P/E(ttm) is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.30 vs. TPI: 2.90 )
TPI' s 10-Year P/E(ttm) Range
Min: 1.61   Max: 81.02
Current: 2.9

1.61
81.02
P/B 0.18
TPI's P/B is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. TPI: 0.18 )
TPI' s 10-Year P/B Range
Min: 0.15   Max: 2.76
Current: 0.18

0.15
2.76
P/S 0.33
TPI's P/S is ranked higher than
98% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. TPI: 0.33 )
TPI' s 10-Year P/S Range
Min: 0.19   Max: 3.54
Current: 0.33

0.19
3.54
PFCF 1.75
TPI's PFCF is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TPI: 1.75 )
TPI' s 10-Year PFCF Range
Min: 1.61   Max: 100
Current: 1.75

1.61
100
EV-to-EBIT -1.27
TPI's EV-to-EBIT is ranked higher than
50% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.72 vs. TPI: -1.27 )
TPI' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 19.3
Current: -1.27

0.1
19.3
Shiller P/E 1.93
TPI's Shiller P/E is ranked higher than
99% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 150.63 vs. TPI: 1.93 )
TPI' s 10-Year Shiller P/E Range
Min: 1.49   Max: 3.35
Current: 1.93

1.49
3.35
Current Ratio 6.27
TPI's Current Ratio is ranked higher than
90% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. TPI: 6.27 )
TPI' s 10-Year Current Ratio Range
Min: 0.06   Max: 6.89
Current: 6.27

0.06
6.89
Quick Ratio 5.51
TPI's Quick Ratio is ranked higher than
90% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. TPI: 5.51 )
TPI' s 10-Year Quick Ratio Range
Min: 0.06   Max: 6.15
Current: 5.51

0.06
6.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.72
TPI's Price/Net Cash is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TPI: 0.72 )
TPI' s 10-Year Price/Net Cash Range
Min: 0.71   Max: 9.48
Current: 0.72

0.71
9.48
Price/Net Current Asset Value 0.53
TPI's Price/Net Current Asset Value is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. TPI: 0.53 )
TPI' s 10-Year Price/Net Current Asset Value Range
Min: 0.46   Max: 5.39
Current: 0.53

0.46
5.39
Price/Tangible Book 0.23
TPI's Price/Tangible Book is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. TPI: 0.23 )
TPI' s 10-Year Price/Tangible Book Range
Min: 0.19   Max: 3.24
Current: 0.23

0.19
3.24
Price/DCF (Projected) 0.19
TPI's Price/DCF (Projected) is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.06 vs. TPI: 0.19 )
TPI' s 10-Year Price/DCF (Projected) Range
Min: 0.16   Max: 0.43
Current: 0.19

0.16
0.43
Price/Median PS Value 0.60
TPI's Price/Median PS Value is ranked higher than
95% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. TPI: 0.60 )
TPI' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 5.19
Current: 0.6

0.38
5.19
Price/Graham Number 0.19
TPI's Price/Graham Number is ranked higher than
100% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.75 vs. TPI: 0.19 )
TPI' s 10-Year Price/Graham Number Range
Min: 0.14   Max: 1.74
Current: 0.19

0.14
1.74
Earnings Yield (Greenblatt) 1487.50
TPI's Earnings Yield (Greenblatt) is ranked higher than
100% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. TPI: 1487.50 )
TPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.2   Max: 6688.7
Current: 1487.5

5.2
6688.7
Forward Rate of Return (Yacktman) 1.65
TPI's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 633 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.43 vs. TPI: 1.65 )
TPI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -2.3   Max: 27.3
Current: 1.65

-2.3
27.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:60T.Germany
Tianyin Pharmaceutical Co., Inc was organized under the laws of the State of Delaware on August 20, 2002. It was formerly called Viscorp, Inc. In March 2006, Tianyin changed its status from an LLC to a corporation registered in the State of Delaware. It is a pharmaceutical company which through its indirect wholly-owned subsidiary Chengdu Tianyin Pharmaceutical Co., Ltd., a corporation organized and existing under the laws of the People's Republic of China. The Company is engaged primarily in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and other pharmaceuticals in China. The Company currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. It sells its prescription-based and OTC TCM and pharmaceutical products via regional distributors as well as directly to the hospitals, clinics, and pharmacies in China. The Company faces competition from domestic TCM manufacturers, as well as domestic and foreign pharmaceuticals with similar therapeutic effects. It uses over 120 different medicinal herbs as primary raw materials and procures its raw materials from various vendors and suppliers. The Company's manufacturing operations are subject to numerous laws, regulations, rules and specifications relating to human health and safety and the environment which address and regulate, among other matters, wastewater discharge, air quality and the generation, handling, storage, treatment, disposal and transportation of solid and hazardous wastes and releases of hazardous substances into the environment.
» More Articles for AMEX:TPI

Headlines

Articles On GuruFocus.com
5 year low Apr 21 2013 
8 Healthcare Dividend Stocks Close To 52-Week Low Sep 03 2011 
18 Low Beta Healthcare Stocks With Best Dividend Yields Jul 02 2011 
High Yields In Healthcare Sector May 26 2011 
Tianyin Pharmaceutical Co., Inc. Receives Production License to Launch Tongbianling Capsules Dec 22 2008 

More From Other Websites
TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) Aug 28 2014
Qionglai Facility (QLF) Schedules September for GMP Examination Aug 18 2014
Testing Runs Progress Updates for TPI's Qionglai Facility Aug 04 2014
TPI Targets Early August 2014 to Start Qionglai Facility (QLF) GMP Inspection Jul 14 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K/A, Other Events Jul 08 2014
TPI Receives GMP for Tablets Formulation in Early July Jul 07 2014
TPI Attends CPhI to Facilitate Azithromycin API Export Business Jun 29 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K/A, Other Events Jun 23 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... May 28 2014
TIANYIN PHARMACEUTICAL CO., INC. Financials May 23 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements... May 19 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 10-Q, Quarterly Report May 15 2014
Tianyin Pharmaceutical's (TPI) F3Q 2014 Results - Earnings Call Transcript May 15 2014
TPI Reports Third Quarter Fiscal Year 2014 Financial Results May 15 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K/A, Other Events May 14 2014
TPI Provides Updates on Annual Meeting May 11 2014
TPI to Host Third Quarter Fiscal Year 2014 Earnings Conference Call on Thursday, May 15, 2014 at... May 08 2014
TIANYIN PHARMACEUTICAL CO., INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... May 06 2014
TPI Presented at Guosen Securities Investment Conference at Shenzhen, China Apr 24 2014
JCM Updates on Azithromycin API Export Apr 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK